ADRB2 and cancer: Both β1 and β2 adrenergic receptors (β1AR, β2AR) are widely targeted by β‐blockers to treat conditions such as hypertension or cardiac arrhythmia, and more recently, growing evidence has supported the antitumor effect of β‐blockers for some cancer types [6, 7].